[Edaily Reporter YU JIN-HEE ] PROTIA(303360), a company specializing in in vitro diagnostics, achieved record-breaking cumulative earnings for the first three quarters of this year despite an unfavorable external environment marked by global geopolitical risks. The rapid growth of its flagship next-generation allergy diagnostic products drove both revenue expansion and improved profitability.

According to the Financial Supervisory Service’s electronic disclosure system on the 11th, PROTIA’s cumulative consolidated revenue for the first three quarters of 2026 reached 13.84 billion won, a 30.9% increase compared to the same period last year (10.57 billion won).

Profitability metrics also improved significantly. Operating profit for the same period rose 34.3% year-over-year (from 2.63 billion won) to 3.53 billion won. Net income before income taxes also increased by 20.9% year-over-year to 3.46 billion won, demonstrating robust earnings strength.

These strong results were largely driven by qualitative growth in the allergy diagnostics division, the company’s core cash cow. In particular, the premium strategic product “PROTIA Allergy-Q 192D,” launched in 2025, took the domestic market by storm and drove earnings.

This product not only offers the widest range of test items among global line-based allergy multiplex diagnostic technologies but also dramatically improved diagnostic accuracy by adopting a recombinant protein-based molecular diagnostic technique. Leveraging its ability to simultaneously diagnose allergies caused by antibiotics and chemical substances, it boosted domestic sales of the “Allergy-Q” line by more than 50% compared to the same period last year.

Building on these strong results, PROTIA plans to embark on full-scale global expansion starting in the fourth quarter. This is because overseas sales channels have opened wide following the CE IVDR certification obtained by PROTIA’s Allergy-Q 192D on the 6th.

Lim Guk-jin, CEO of PROTIA, emphasized, “Our flagship allergy diagnostic product, which has proven its competitiveness in the domestic market, has recently successfully completed CE IVDR certification, paving the way for our entry into overseas markets.” He added, “With our autoimmune diagnostic product line—which also obtained certification—now entering full-scale export, we expect to see rapid growth, particularly in high-margin global markets.”